抗心律失常药物治疗时间对难治性院外心脏骤停生存与神经结局的影响
该研究是对复苏结局联盟胺碘酮、利多卡因、安慰剂随机对照试验的事后分析,纳入成人非创伤性院外心脏骤停且初始心律为心室颤动或无脉性室性心动过速、至少一次除颤无效的患者。3,026例中2,994例(99%)有治疗时间数据。随给药时间延长,胺碘酮组(OR 0.91;95%CI 0.90-0.93/分钟)、利多卡因组(OR 0.93;95%CI 0.91-0.96)和安慰剂组(OR 0.91;95%CI 0.90-0.93)出院生存比例均下降。与安慰剂相比,胺碘酮在所有给药时间点均改善生存(OR 1.32;95%CI 1.05-1.65);利多卡因在给药时间<11分钟时生存无差异,在较晚时间点生存更高,治疗效应与时间存在交互作用(p=0.048)。良好神经结局的分析结果相似。
要点
- 难治性院外心脏骤停给药越晚,出院生存越低:胺碘酮组OR 0.91(95%CI 0.90-0.93/分钟)、利多卡因组OR 0.93(95%CI 0.91-0.96)、安慰剂组OR 0.91(95%CI 0.90-0.93)。
- 与安慰剂相比,胺碘酮在所有给药时间点均改善出院生存(OR 1.32;95%CI 1.05-1.65)。
- 利多卡因与安慰剂相比,给药时间<11分钟时生存无差异,较晚时间点生存更高,治疗效应与时间存在交互作用(p=0.048)。
- 良好神经结局(改良Rankin量表≤3)的分析结果与生存结果相似。
- 3,026例患者中2,994例(99%)有治疗时间数据,分析来自复苏结局联盟胺碘酮、利多卡因、安慰剂随机对照试验的事后分析。
适用人群与场景
- 成人非创伤性院外心脏骤停,初始心律为心室颤动或无脉性室性心动过速,且至少一次除颤尝试无效。
- 数据来自北美多个站点的急救医疗服务纳入的患者。
研究设计与关键结果
- 研究设计:复苏结局联盟胺碘酮、利多卡因、安慰剂随机对照试验的事后分析,纳入3,026例患者,其中2,994例(99%)有治疗时间数据。
- 主要终点:随时间推移至给药延长,出院生存比例下降,胺碘酮组OR 0.91(95%CI 0.90-0.93/分钟)、利多卡因组OR 0.93(95%CI 0.91-0.96)、安慰剂组OR 0.91(95%CI 0.90-0.93)。
- 胺碘酮与安慰剂比较:在所有给药时间点均改善生存(OR 1.32;95%CI 1.05-1.65)。
- 利多卡因与安慰剂比较:给药时间<11分钟时生存无差异,较晚时间点生存更高,治疗效应与时间存在交互作用(p=0.048)。
- 良好神经结局(出院时改良Rankin量表≤3)的分析结果与生存结果相似。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在难治性院外心脏骤停中,抗心律失常药物给药越晚,出院生存和良好神经结局越差;与安慰剂相比,胺碘酮在所有时间点改善生存,而利多卡因仅在较晚时间点改善生存。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Examining the association of time to treatment (drug or placebo) with survival to hospital discharge and neurologic outcome.
DESIGN: Post hoc analysis of the Resuscitation Outcomes Consortium Amiodarone, Lidocaine, Placebo randomized controlled trial.
SETTING: Emergency medical services enrolled patients with out-of-hospital cardiac arrest (OHCA) at multiple North American sites.
PATIENTS: Adults with nontraumatic OHCA and an initial rhythm of ventricular fibrillation or pulseless ventricular tachycardia refractory to at least one defibrillation attempt were included.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We used logistic regression to examine the association of time to treatment with survival to hospital discharge and favorable neurologic status at discharge (modified Rankin Scale ≤ 3) for the three treatment groups including an interaction term between treatment and time to treatment to determine the effect of time on treatment effects. Time to treatment data were available for 2,994 out of 3,026 patients (99%). The proportion of patients who survived to hospital discharge decreased as time to drug administration increased, in amiodarone (odds ratio [OR], 0.91; 95% CI, 0.90-0.93 per min), lidocaine (OR, 0.93; 95% CI, 0.91-0.96), and placebo (OR, 0.91; 95% CI, 0.90-0.93). Comparing amiodarone to placebo, there was improved survival at all times of drug administration (OR, 1.32; 95% CI, 1.05-1.65). Comparing lidocaine to placebo, survival was not different with shorter times to drug administration (< 11 min), whereas survival was higher with lidocaine at longer times to drug administration with an interaction between treatment effect and time to treatment (p = 0.048). Survival with good neurologic outcome showed similar results for all analyses.
CONCLUSIONS: Survival and favorable neurologic outcomes decreased with longer times to drug administration. Amiodarone improved survival at all time points whereas lidocaine improved survival only at later time points, compared with placebo.
参考来源
- Rahimi M, Dorian P, Cheskes S, et al. The Effect of Time to Treatment With Antiarrhythmic Drugs on Survival and Neurological Outcomes in Shock Refractory Out-of-Hospital Cardiac Arrest. Crit Care Med. 2023. PMID: 37318289. doi:10.1097/CCM.0000000000005846
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。